Regulation of PGE2 and PGI2 release from human umbilical vein endothelial cells by actin cytoskeleton

Sara J. Sawyer, Suzanne M. Norvell, Suzanne M. Ponik, Fredrick Pavalko

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Disruption of microfilaments in human umbilical vein endothelial cells (HUVEC) with cytochalasin D (cytD) or latrunculin A (latA) resulted in a 3.3- to 5.7-fold increase in total synthesis of prostaglandin E2 (PGE2) and a 3.4- to 6.5-fold increase in prostacyclin (PGI2) compared with control cells. Disruption of the microtubule network with nocodazole or colchicine increased synthesis of PGE2 1.7- to 1.9-fold and PGI2 1.9- to 2.0-fold compared with control cells. Interestingly, however, increased release of PGE2 and PGI2 from HUVEC into the media occurred only when microfilaments were disrupted. CytD treatment resulted in 6.7-fold more PGE2 and 3.8-fold more PGI2 released from HUVEC compared with control cells; latA treatment resulted in 17.7-fold more PGE2 and 11.2-fold more PGI2 released compared with control cells. Both increased synthesis and release of prostaglandins in response to all drug treatments were completely inhibited by NS-398, a specific inhibitor of cyclooxygenase-2 (COX-2). Disruption of either microfilaments using cytD or latA or of microtubules using nocodazole or colchicine resulted in a significant increase in COX-2 protein levels, suggesting that the increased synthesis of prostaglandins in response to drug treatments may result from increased activity of COX-2. These results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest that the cytoskeleton plays an important role in maintenance of endothelial barrier function by regulating prostaglandin synthesis and release from HUVEC.

Original languageEnglish
JournalAmerican Journal of Physiology - Cell Physiology
Volume281
Issue number3 50-3
StatePublished - 2001

Fingerprint

Endothelial cells
Human Umbilical Vein Endothelial Cells
Epoprostenol
Actin Cytoskeleton
Dinoprostone
Actins
Prostaglandins
Nocodazole
Drug therapy
Cytochalasin D
Colchicine
Cyclooxygenase 2
Microtubules
Cyclooxygenase 2 Inhibitors
Cytoskeleton
Pharmaceutical Preparations
Maintenance
latrunculin A
Proteins

Keywords

  • Cyclooxygenase
  • Microfilaments
  • Microtubules
  • Prostacyclin
  • Prostaglandin E2
  • Vasoprotection

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology
  • Physiology (medical)

Cite this

Regulation of PGE2 and PGI2 release from human umbilical vein endothelial cells by actin cytoskeleton. / Sawyer, Sara J.; Norvell, Suzanne M.; Ponik, Suzanne M.; Pavalko, Fredrick.

In: American Journal of Physiology - Cell Physiology, Vol. 281, No. 3 50-3, 2001.

Research output: Contribution to journalArticle

@article{33bea9a51bd7406792cfb9961b2f19df,
title = "Regulation of PGE2 and PGI2 release from human umbilical vein endothelial cells by actin cytoskeleton",
abstract = "Disruption of microfilaments in human umbilical vein endothelial cells (HUVEC) with cytochalasin D (cytD) or latrunculin A (latA) resulted in a 3.3- to 5.7-fold increase in total synthesis of prostaglandin E2 (PGE2) and a 3.4- to 6.5-fold increase in prostacyclin (PGI2) compared with control cells. Disruption of the microtubule network with nocodazole or colchicine increased synthesis of PGE2 1.7- to 1.9-fold and PGI2 1.9- to 2.0-fold compared with control cells. Interestingly, however, increased release of PGE2 and PGI2 from HUVEC into the media occurred only when microfilaments were disrupted. CytD treatment resulted in 6.7-fold more PGE2 and 3.8-fold more PGI2 released from HUVEC compared with control cells; latA treatment resulted in 17.7-fold more PGE2 and 11.2-fold more PGI2 released compared with control cells. Both increased synthesis and release of prostaglandins in response to all drug treatments were completely inhibited by NS-398, a specific inhibitor of cyclooxygenase-2 (COX-2). Disruption of either microfilaments using cytD or latA or of microtubules using nocodazole or colchicine resulted in a significant increase in COX-2 protein levels, suggesting that the increased synthesis of prostaglandins in response to drug treatments may result from increased activity of COX-2. These results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest that the cytoskeleton plays an important role in maintenance of endothelial barrier function by regulating prostaglandin synthesis and release from HUVEC.",
keywords = "Cyclooxygenase, Microfilaments, Microtubules, Prostacyclin, Prostaglandin E2, Vasoprotection",
author = "Sawyer, {Sara J.} and Norvell, {Suzanne M.} and Ponik, {Suzanne M.} and Fredrick Pavalko",
year = "2001",
language = "English",
volume = "281",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "3 50-3",

}

TY - JOUR

T1 - Regulation of PGE2 and PGI2 release from human umbilical vein endothelial cells by actin cytoskeleton

AU - Sawyer, Sara J.

AU - Norvell, Suzanne M.

AU - Ponik, Suzanne M.

AU - Pavalko, Fredrick

PY - 2001

Y1 - 2001

N2 - Disruption of microfilaments in human umbilical vein endothelial cells (HUVEC) with cytochalasin D (cytD) or latrunculin A (latA) resulted in a 3.3- to 5.7-fold increase in total synthesis of prostaglandin E2 (PGE2) and a 3.4- to 6.5-fold increase in prostacyclin (PGI2) compared with control cells. Disruption of the microtubule network with nocodazole or colchicine increased synthesis of PGE2 1.7- to 1.9-fold and PGI2 1.9- to 2.0-fold compared with control cells. Interestingly, however, increased release of PGE2 and PGI2 from HUVEC into the media occurred only when microfilaments were disrupted. CytD treatment resulted in 6.7-fold more PGE2 and 3.8-fold more PGI2 released from HUVEC compared with control cells; latA treatment resulted in 17.7-fold more PGE2 and 11.2-fold more PGI2 released compared with control cells. Both increased synthesis and release of prostaglandins in response to all drug treatments were completely inhibited by NS-398, a specific inhibitor of cyclooxygenase-2 (COX-2). Disruption of either microfilaments using cytD or latA or of microtubules using nocodazole or colchicine resulted in a significant increase in COX-2 protein levels, suggesting that the increased synthesis of prostaglandins in response to drug treatments may result from increased activity of COX-2. These results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest that the cytoskeleton plays an important role in maintenance of endothelial barrier function by regulating prostaglandin synthesis and release from HUVEC.

AB - Disruption of microfilaments in human umbilical vein endothelial cells (HUVEC) with cytochalasin D (cytD) or latrunculin A (latA) resulted in a 3.3- to 5.7-fold increase in total synthesis of prostaglandin E2 (PGE2) and a 3.4- to 6.5-fold increase in prostacyclin (PGI2) compared with control cells. Disruption of the microtubule network with nocodazole or colchicine increased synthesis of PGE2 1.7- to 1.9-fold and PGI2 1.9- to 2.0-fold compared with control cells. Interestingly, however, increased release of PGE2 and PGI2 from HUVEC into the media occurred only when microfilaments were disrupted. CytD treatment resulted in 6.7-fold more PGE2 and 3.8-fold more PGI2 released from HUVEC compared with control cells; latA treatment resulted in 17.7-fold more PGE2 and 11.2-fold more PGI2 released compared with control cells. Both increased synthesis and release of prostaglandins in response to all drug treatments were completely inhibited by NS-398, a specific inhibitor of cyclooxygenase-2 (COX-2). Disruption of either microfilaments using cytD or latA or of microtubules using nocodazole or colchicine resulted in a significant increase in COX-2 protein levels, suggesting that the increased synthesis of prostaglandins in response to drug treatments may result from increased activity of COX-2. These results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest that the cytoskeleton plays an important role in maintenance of endothelial barrier function by regulating prostaglandin synthesis and release from HUVEC.

KW - Cyclooxygenase

KW - Microfilaments

KW - Microtubules

KW - Prostacyclin

KW - Prostaglandin E2

KW - Vasoprotection

UR - http://www.scopus.com/inward/record.url?scp=0034823920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034823920&partnerID=8YFLogxK

M3 - Article

C2 - 11502582

AN - SCOPUS:0034823920

VL - 281

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 3 50-3

ER -